Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172148 | 1.00 | TACR2 (0.59) | TACR2TACR1 | |
| SCHEMBL6170464 | 0.86 | TACR2 (0.65) | TACR2TACR1 | |
| SCHEMBL6172770 | 0.84 | TACR2 (0.62) | TACR2TACR1 | |
| SCHEMBL6172157 | 0.84 | TACR2 (0.60) | TACR2TACR1 | |
| SCHEMBL6768914 | 0.77 | TACR2 (0.60) | TACR2TACR1 | |
| SCHEMBL6171293 | 0.77 | TACR2 (0.64) | TACR2TACR1 | |
| SCHEMBL9008733 | 0.75 | TACR2 (0.83) | TACR2TACR1 | |
| SCHEMBL759334 | 0.74 | TACR2 (0.82) | TACR2TACR1 | |
| SCHEMBL6170809 | 0.74 | TACR2 (0.82) | TACR2TACR1 | |
| SCHEMBL6171048 | 0.74 | TACR2 (0.64) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1293506-B1 | New 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazine derivatives, process for their preparation and pharmaceutical compositions containing the same | SOLVAY PHARM GMBH (DE) | 2005-09-28 | — | — | EP | claimed |
| US-6770649-B2 | PIPERIZINE COMPOUNDS USEFUL FOR TREATING IRRITABLE BOWEL SYNDROME | SOLVAY PHARMACEUTICALS GMBH (DE) | 2004-08-03 | — | — | US | claimed |
| US-20030125557-A1 | 1-[1-(hetero) aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-07-03 | — | — | US | claimed |
| EP-1293506-A1 | New 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazine derivatives, process for their preparation and pharmaceutical compositions containing the same | Solvay Pharmaceuticals GmbH (DE) | 2003-03-19 | — | — | EP | claimed |
| EP-1293506-B1 | New 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazine derivatives, process for their preparation and pharmaceutical compositions containing the same | SOLVAY PHARM GMBH (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-6770649-B2 | PIPERIZINE COMPOUNDS USEFUL FOR TREATING IRRITABLE BOWEL SYNDROME | SOLVAY PHARMACEUTICALS GMBH (DE) | 2004-08-03 | — | — | US | disclosed |
| US-20030125557-A1 | 1-[1-(hetero) aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-07-03 | — | — | US | disclosed |
| EP-1293506-A1 | New 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazine derivatives, process for their preparation and pharmaceutical compositions containing the same | Solvay Pharmaceuticals GmbH (DE) | 2003-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125557-A1 | 1-[1-(hetero) aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and pharmaceutical compositions containing them | HTR7, OPRL1, HTR6 | TACR2 11/4885TACR1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.